Ten years' real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer.

Fernando JerkovichSoledad CapalboErika Abelleira Fabián Pitoia

Published in: Endocrine (2024)

TKIs demonstrated efficacy and tolerability comparable to real-world data in RR-DTC. PFS was not statistically different between sorafenib and lenvatinib. Our study will help guide physicians in making informed decisions regarding treatment sequencing with TKIs in these patients.

Keyphrases

end stage renal disease
primary care
newly diagnosed
ejection fraction
prognostic factors
electronic health record
open label
single cell
machine learning
big data
artificial intelligence
replacement therapy
study protocol